Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Bladder Cancer, September 2019

Free Subscription


Abstracts

Retrieve all available abstracts of the following 147 articles:
HTML format


 

Single Articles

  1. GOMELLA LG
    Viral Therapy for Bladder Cancer: Everything Old is New Again.
    Can J Urol. 2019;26:9802.
    Abstract    



  2. PENG J, Ye L, Li T, Zhu Q, et al
    Irradiated Bladder Cancer Cells Expressing both GM-CSF and IL-21 versus Either GM-CSF or IL-21 Alone as Tumor Vaccine in a Mouse Xenograft Model.
    Biomed Res Int. 2019;2019:8262989.
    Abstract    

    Abstract available

  3. CHEN S, Zhu S, Cui X, Xu W, et al
    Identifying non-muscle-invasive and muscle-invasive bladder cancer based on blood serum surface-enhanced Raman spectroscopy.
    Biomed Opt Express. 2019;10:3533-3544.
    Abstract    

    Abstract available

  4. LU J, Zhong F, Sun B, Wang C, et al
    GPR137 is a promising novel bio-marker for the prognosis of bladder cancer patients.
    Medicine (Baltimore). 2019;98:e16576.
    Abstract    

    Abstract available

  5. XIN F, Yao DW, Fan L, Liu JH, et al
    Adenylate kinase 4 promotes bladder cancer cell proliferation and invasion.
    Clin Exp Med. 2019 Aug 28. pii: 10.1007/s10238-019-00576.
    Abstract    

    Abstract available

  6. ZAMBONI S, Moschini M, Antonelli A, Simeone C, et al
    How to improve patient selection for neoadjuvant chemotherapy in bladder cancer patients candidate for radical cystectomy and pelvic lymph node dissection.
    World J Urol. 2019 Aug 28. pii: 10.1007/s00345-019-02916.
    Abstract    

    Abstract available

  7. SOUTHERN JB, Bhattacharya P, Clifton MM, Park A, et al
    Perioperative management of cold agglutinin autoimmune hemolytic anemia in an older adult undergoing radical cystectomy for bladder cancer.
    Urol Case Rep. 2019;27:100998.
    Abstract    

    Abstract available

  8. WU L, Zhang M, Qi L, Zu X, et al
    ERalpha-mediated alterations in circ_0023642 and miR-490-5p signaling suppress bladder cancer invasion.
    Cell Death Dis. 2019;10:635.
    Abstract    

    Abstract available

  9. CHEN H, Chen L, Liu F, Lu J, et al
    Diffusion-weighted magnetic resonance imaging in bladder cancer: comparison of readout-segmented and single-shot EPI techniques.
    Cancer Imaging. 2019;19:59.
    Abstract    

    Abstract available

  10. WU Y, Zheng Q, Li Y, Wang G, et al
    Metformin targets a YAP1-TEAD4 complex via AMPKalpha to regulate CCNE1/2 in bladder cancer cells.
    J Exp Clin Cancer Res. 2019;38:376.
    Abstract    

    Abstract available

  11. SONG Y, Chen J, Liu K, Zhou K, et al
    Glutathione S-Transferase Pi 1 (GSTP1) Gene 313 A/G (rs1695) polymorphism is associated with the risk of urinary bladder cancer: Evidence from a systematic review and meta-analysis based on 34 case-control studies.
    Gene. 2019 Aug 24:144077. doi: 10.1016/j.gene.2019.144077.
    Abstract    

    Abstract available

  12. WROCLAWSKI ML, Schutz FA, Cha JD, Soares A, et al
    Alternative Therapies to Bacillus Calmette-Guerin Shortage for Nonmuscle Invasive Bladder Cancer in Brazil and Other Underdeveloped Countries: Management Considerations.
    J Glob Oncol. 2019;5:1-9.
    Abstract    

    Abstract available

  13. ZHOU J, Li L, Li X, Yu Q, et al
    Efficacy analysis of a novel thermochemotherapy scheme with pirarubicin for intermediate- and high-risk nonmuscle-invasive bladder cancer: a single-institution nonrandomized concurrent controlled trial.
    Int J Hyperthermia. 2019;36:868-875.
    Abstract    

    Abstract available

  14. PEPPAS I, Sollie S, Josephs DH, Hammar N, et al
    Serum immunoglobulin levels and the risk of bladder cancer in the AMORIS Cohort.
    Cancer Epidemiol. 2019 Aug 23:101584. doi: 10.1016/j.canep.2019.101584.
    Abstract    

    Abstract available

  15. SHI F, Deng Z, Zhou Z, Jiang CY, et al
    QKI-6 inhibits bladder cancer malignant behaviours through down-regulating E2F3 and NF-kappaB signalling.
    J Cell Mol Med. 2019 Aug 26. doi: 10.1111/jcmm.14481.
    Abstract    

    Abstract available

  16. BASTOS J, Miranda MA, Mondal A, Sachdeva M, et al
    Chemosensitizing effect of cernumidine extracted from Solanum cernuum Vell. on bladder cancer cells in vitro.
    Chem Biodivers. 2019 Aug 25. doi: 10.1002/cbdv.201900334.
    Abstract    

    Abstract available

  17. OHADIAN MOGHADAM S, Nowroozi MR
    Toll-like receptors: The role in bladder cancer development, progression and immunotherapy.
    Scand J Immunol. 2019 Aug 26:e12818. doi: 10.1111/sji.12818.
    Abstract    

    Abstract available

  18. YIN XH, Jin YH, Cao Y, Wong Y, et al
    Development of a 21-miRNA Signature Associated With the Prognosis of Patients With Bladder Cancer.
    Front Oncol. 2019;9:729.
    Abstract    

    Abstract available

  19. OKSUZ E, Bugday MS
    Can intravesical application of paracetamol benefit the chemotherapy treatment of bladder cancer?
    Med Hypotheses. 2019;131:109322.
    Abstract    

    Abstract available

  20. DEL POZO JIMENEZ G, Herranz Amo F, Diez Cordero JM, Monzo Gardiner JI, et al
    [Prognostic factors of mortality in patients with urothelial bladder tumor treated with radical cistectomy.]
    Arch Esp Urol. 2019;72:451-462.
    Abstract    

    Abstract available

  21. KONDO A, Sasaki T, Kitaguchi D, Tsukada Y, et al
    Resection of the urinary bladder for locally advanced colorectal cancer: a retrospective comparison of partial versus total cystectomy.
    BMC Surg. 2019;19:63.
    Abstract    

    Abstract available

  22. OSMANOV YI, Gaibov JA, Kogan EA, Rapoport LM, et al
    [Molecular basis of intratumoral heterogeneity of urinary tract urothelial carcinoma].
    Urologiia. 2019;:126-130.
    Abstract    

    Abstract available

  23. POPOV SV, Skryabin ON, Orlov IN, Suleymanov MM, et al
    [Comparative analysis of results in laparoscopic radical cystectomy with extracorporeal and intracorporeal neobladder formation].
    Urologiia. 2019;:68-72.
    Abstract    

    Abstract available

  24. GROVES A, Gleeson M, Spigelman AD
    NTHL1-associate polyposis: first Australian case report.
    Fam Cancer. 2019;18:179-182.
    Abstract    

    Abstract available

  25. MA X, Hadjiiski LM, Wei J, Chan HP, et al
    U-Net based deep learning bladder segmentation in CT urography.
    Med Phys. 2019;46:1752-1765.
    Abstract    

    Abstract available

  26. HONG JY, Jung GJ, Li K
    Acquired Cutaneous Lymphangiectasia Secondary to Cervical Cancer Treatment.
    Am J Dermatopathol. 2018 Oct 4. doi: 10.1097/DAD.0000000000001127.
    Abstract    



  27. LEI Y, Yang L, Hongwei J, Hongyuan Y, et al
    TIS111D can affect bladder cancer cells by regulating epithelial-mesenchymal transition.
    Life Sci. 2019 Sep 3:116832. doi: 10.1016/j.lfs.2019.116832.
    Abstract    

    Abstract available

  28. JIAN X, Shen M, Liao G
    Definitive BCG immunotherapy versus radical cystectomy in intermediate or high-risk nonmuscle invasive bladder cancer patients: A retrospective study.
    Medicine (Baltimore). 2019;98:e16873.
    Abstract    

    Abstract available

  29. DELCOURT C, Gemival P, Nouhaud FX, Gobet F, et al
    Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC).
    World J Urol. 2019 Sep 5. pii: 10.1007/s00345-019-02896.
    Abstract    

    Abstract available

  30. DAI L, Chai CM, Shen TY, Tian Y, et al
    LncRNA ITGB1 promotes the development of bladder cancer through regulating microRNA-10a expression.
    Eur Rev Med Pharmacol Sci. 2019;23:6858-6867.
    Abstract    

    Abstract available

  31. NIU L, Gao Z, Cui Y, Yang X, et al
    Thyroid Receptor-Interacting Protein 13 is Correlated with Progression and Poor Prognosis in Bladder Cancer.
    Med Sci Monit. 2019;25:6660-6668.
    Abstract    

    Abstract available

  32. RELPH K, Annels N, Smith C, Kostalas M, et al
    Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus: Using a Bladder Tumor Precision-Cut Slice Model System to Assess Viral Efficacy.
    Methods Mol Biol. 2020;2058:249-259.
    Abstract    

    Abstract available

  33. BIANCHI FM, Romagnoli D, D'Agostino D, Corsi P, et al
    Is robotic approach useful to palliate advanced bladder cancer? A monocentric single surgeon experience.
    Cent European J Urol. 2019;72:113-120.
    Abstract    

    Abstract available

  34. GRONOSTAJ K, Czech AK, Fronczek J, Wiatr T, et al
    Implementation of neoadjuvant chemotherapy in muscle invasive bladder cancer treatment in Poland: a single institution retrospective study.
    Cent European J Urol. 2019;72:100-105.
    Abstract    

    Abstract available

  35. TANDOGDU Z, Lewis R, Duncan A, Penegar S, et al
    Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness.
    BMJ Open. 2019;9:e022268.
    Abstract    

    Abstract available


  36. Expression of Concern: Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer.
    Cancer Prev Res (Phila). 2019 Sep 3. pii: 1940-6207.CAPR-19-0406.
    Abstract    



  37. RICHTERS A, Dickman PW, Witjes JA, Boormans JL, et al
    Bladder cancer survival: Women only fare worse in the first two years after diagnosis.
    Urol Oncol. 2019 Aug 31. pii: S1078-1439(19)30319.
    Abstract    

    Abstract available

  38. BI J, Liu H, Dong W, Xie W, et al
    Circular RNA circ-ZKSCAN1 inhibits bladder cancer progression through miR-1178-3p/p21 axis and acts as a prognostic factor of recurrence.
    Mol Cancer. 2019;18:133.
    Abstract    

    Abstract available

  39. MATARAZZO S, Melocchi L, Rezzola S, Grillo E, et al
    Long Pentraxin-3 Follows and Modulates Bladder Cancer Progression.
    Cancers (Basel). 2019;11.
    Abstract    

    Abstract available

  40. LIAN P, Wang Q, Zhao Y, Chen C, et al
    An eight-long non-coding RNA signature as a candidate prognostic biomarker for bladder cancer.
    Aging (Albany NY). 2019;11.
    Abstract    

    Abstract available

  41. WANG X, Ni X, Tang G
    Prognostic Role of Platelet-to-Lymphocyte Ratio in Patients With Bladder Cancer: A Meta-Analysis.
    Front Oncol. 2019;9:757.
    Abstract    

    Abstract available

  42. DANIELS MJ, Barry E, Milbar N, Schoenberg M, et al
    An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle-invasive bladder cancer.
    Urol Oncol. 2019 Aug 28. pii: S1078-1439(19)30299.
    Abstract    

    Abstract available

  43. KARIM S, Mackillop WJ, Brennan K, Peng Y, et al
    Estimating the optimal perioperative chemotherapy utilization rate for muscle-invasive bladder cancer.
    Cancer Med. 2019 Aug 31. doi: 10.1002/cam4.2449.
    Abstract    

    Abstract available

  44. HIROSE Y, Kinoshita A, Ishii A, Ishimoto U, et al
    [Successful treatment of unresectable advanced gastric cancer with bladder metastasis using mFOLFOX6:a case report].
    Nihon Shokakibyo Gakkai Zasshi. 2019;116:676-684.
    Abstract    

    Abstract available

  45. ZHU F, Zhang Y, Shi L, Wu CL, et al
    Gene mutation detection of urinary sediment cells for NMIBC early diagnose and prediction of NMIBC relapse after surgery.
    Medicine (Baltimore). 2019;98:e16451.
    Abstract    

    Abstract available

  46. RODRIGUEZ PENA MDC, Chaux A, Eich ML, Tregnago AC, et al
    Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder.
    Virchows Arch. 2019;475:349-356.
    Abstract    

    Abstract available

  47. WILEY C, Wise CF, Breen M
    Novel Noninvasive Diagnostics.
    Vet Clin North Am Small Anim Pract. 2019;49:781-791.
    Abstract    

    Abstract available

  48. SAGEHASHI R, Ichimura Y, Iinuma M
    [Primary Adenocarcinoma of the Bladder at the Vesicocutaneostomy Site Occuring 30 Years after the Operation].
    Hinyokika Kiyo. 2019;65:167-170.
    Abstract    

    Abstract available

  49. ROMAGNOLI D, Bianchi FM, Corsi P, D'Agostino D, et al
    Robot-Assisted Radical Cystectomy with Intracorporeal Orthotopic Ileal Neobladder: A Safe Strategy in Elderly Patients? Results of Propensity Score Matching in a Single High-Volume Center.
    Surg Technol Int. 2019;34:302-309.
    Abstract    

    Abstract available

  50. BERCHIOLLI R, Mocellin DM, Marconi M, Tomei F, et al
    Ruptured Mycotic Aneurysm After Intravesical Instillation for Bladder Tumor.
    Ann Vasc Surg. 2019;59:310.
    Abstract    

    Abstract available

  51. AUDENET F, Sfakianos JP, Waingankar N, Ruel NH, et al
    A delay >/=8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging.
    Urol Oncol. 2019;37:116-122.
    Abstract    

    Abstract available

  52. MICHELS CTJ, Wijburg CJ, Abma IL, Witjes JA, et al
    Translation and validation of two disease-specific patient-reported outcome measures (Bladder Cancer Index and FACT-Bl-Cys) in Dutch bladder cancer patients.
    J Patient Rep Outcomes. 2019;3:62.
    Abstract    

    Abstract available

  53. SHARIFI L, Nowroozi MR, Amini E, Arami MK, et al
    A review on the role of M2 macrophages in bladder cancer; pathophysiology and targeting.
    Int Immunopharmacol. 2019;76:105880.
    Abstract    

    Abstract available

  54. ROGGISCH J, Ecke T, Koch S
    Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer.
    Urol Oncol. 2019 Sep 11. pii: S1078-1439(19)30325.
    Abstract    

    Abstract available

  55. VAN HEMELRIJCK M, Sparano F, Josephs D, Sprangers M, et al
    Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review.
    BMC Urol. 2019;19:86.
    Abstract    

    Abstract available

  56. PIGNOT G, Le Goux C, Vacher S, Schnitzler A, et al
    PLEKHS1: A new molecular marker predicting risk of progression of non-muscle-invasive bladder cancer.
    Oncol Lett. 2019;18:3471-3480.
    Abstract    

    Abstract available

  57. WANG L, Shi J, Huang Y, Liu S, et al
    A six-gene prognostic model predicts overall survival in bladder cancer patients.
    Cancer Cell Int. 2019;19:229.
    Abstract    

    Abstract available

  58. WU L, Yang F, Song L, Xiao Z, et al
    Comparison of intracorporeal and extracorporeal urinary diversions after laparoscopic radical cystectomy in females with bladder cancer.
    World J Surg Oncol. 2019;17:161.
    Abstract    

    Abstract available

  59. KO SH, Han K, Yun JS, Chung S, et al
    Impact of obesity and diabetes on the incidence of kidney and bladder cancers: a nationwide cohort study.
    Eur J Endocrinol. 2019 Sep 1. pii: EJE-19-0500.R2. doi: 10.1530/EJE-19-0500.
    Abstract    

    Abstract available

  60. KAPOOR K, Datta C, Pal DK
    Is liquid-based cytology an alternative to conventional cytology for detection of malignant cells in urine of bladder cancer? Eastern Indian prospective observational study.
    Turk J Urol. 2019;45:351-356.
    Abstract    

    Abstract available

  61. SPACHMANN PJ, Azzolina V, Weber F, Evert M, et al
    Loss of CHEK2 Predicts Progression in Stage pT1 Non-Muscle-Invasive Bladder Cancer (NMIBC).
    Pathol Oncol Res. 2019 Sep 10. pii: 10.1007/s12253-019-00745.
    Abstract    

    Abstract available

  62. WU X, Chen H, Zhang G, Wu J, et al
    MiR-212-3p inhibits cell proliferation and promotes apoptosis by targeting nuclear factor IA in bladder cancer.
    J Biosci. 2019;44.
    Abstract    

    Abstract available

  63. PARK HS, Lee S, Lee J, Shin HB, et al
    Suppression of CD81 promotes bladder cancer cell invasion through increased matrix metalloproteinase expression via extracellular signal-regulated kinase phosphorylation.
    Investig Clin Urol. 2019;60:396-404.
    Abstract    

    Abstract available

  64. SAHIN Y, Yucetas U, Ates HA, Erkan E, et al
    Improving the diagnosis of high grade and stage bladder cancer by detecting increased urinary calprotectin expression in tumor tissue and tumor-associated inflammatory response.
    Investig Clin Urol. 2019;60:343-350.
    Abstract    

    Abstract available

  65. SCHNEIDER AK, Chevalier MF, Derre L
    The multifaceted immune regulation of bladder cancer.
    Nat Rev Urol. 2019 Sep 9. pii: 10.1038/s41585-019-0226.
    Abstract    

    Abstract available

  66. BAO Y, Liu X, Liu Y, Wang S, et al
    Ras-association domain family 1 (RASSF1A) gene regulates progression, migration and invasion of bladder cancer.
    Surg Oncol. 2019;30:63-71.
    Abstract    

    Abstract available

  67. CHOI SY, You D, Hong B, Hong JH, et al
    Impact of lymph node dissection in radical cystectomy for bladder cancer: How many vs how far?
    Surg Oncol. 2019;30:109-116.
    Abstract    

    Abstract available

  68. NAVE O, Hareli S, Elbaz M, Iluz IH, et al
    BCG and IL - 2 model for bladder cancer treatment with fast and slow dynamics based on SPVF method-stability analysis.
    Math Biosci Eng. 2019;16:5346-5379.
    Abstract    

    Abstract available

  69. BOURN J, Pandey S, Uddin J, Marnett L, et al
    Detection of tyrosine kinase inhibitors-induced COX-2 expression in bladder cancer by fluorocoxib A.
    Oncotarget. 2019;10:5168-5180.
    Abstract    

    Abstract available

  70. MAN X, Liu T, Jiang Y, Zhang Z, et al
    Silencing of CARMA3 inhibits bladder cancer cell migration and invasion via deactivating beta-catenin signaling pathway.
    Onco Targets Ther. 2019;12:6309-6322.
    Abstract    

    Abstract available

  71. MCMULLEN CK, Rosetti MO, Weinmann S, Leo MC, et al
    Clinical Use Cases for a Tool to Assess Risk in Superficial Bladder Cancer.
    Perm J. 2019;23.
    Abstract    

    Abstract available

  72. LU J, Zhong F, Sun B, Wang C, et al
    Diagnostic Utility of Serum Golgi Phosphoprotein 3 in Bladder Cancer Patients.
    Med Sci Monit. 2019;25:6736-6741.
    Abstract    

    Abstract available

  73. WINOKER JS, Liaw CW, Galsky MD, Wiklund P, et al
    Clinical Complete Response after Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Call for Standardized Assessments and Definitions.
    Eur Urol Focus. 2019 Sep 4. pii: S2405-4569(19)30227.
    Abstract    

    Abstract available

  74. DAI Z, Yang L, Li Y, Zhao C, et al
    A portable dual-mode sensor based on a TiO2 nanotube membrane for the evaluation of telomerase activity.
    Chem Commun (Camb). 2019;55:10571-10574.
    Abstract    

    Abstract available

  75. ARMAS-ALVAREZ AL, Fernandez-Lopez A, Donate-Moreno MJ, Salinas-Sanchez AS, et al
    [Bladder leiomyomas.]
    Arch Esp Urol. 2019;72:612-615.
    Abstract    

    Abstract available

  76. LINNEHAN B, Snyman H, DeLay J, Mareschal A, et al
    URINARY BLADDER TRANSITIONAL CELL CARCINOMA AND CARCINOMATOSIS IN A LINNAEUS'S TWO-TOED SLOTH, CHOLOEPUS DIDACTYLUS.
    J Zoo Wildl Med. 2019;50:278-281.
    Abstract    

    Abstract available

  77. HWANG EC, Sathianathen NJ, Imamura M, Kuntz GM, et al
    Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy.
    Cochrane Database Syst Rev. 2019;5:CD013336.
    Abstract    

    Abstract available

  78. LUETHCKE KR, Ekena J, Chun R, Trepanier LA, et al
    Glutathione S-transferase theta genotypes and environmental exposures in the risk of canine transitional cell carcinoma.
    J Vet Intern Med. 2019;33:1414-1422.
    Abstract    

    Abstract available

  79. DELL'OGLIO P, Tian Z, Leyh-Bannurah SR, Larcher A, et al
    Development of a New Comorbidity Assessment Tool for Specific Prediction of Perioperative Mortality in Contemporary Patients Treated with Radical Cystectomy.
    Ann Surg Oncol. 2019;26:1942-1949.
    Abstract    

    Abstract available

  80. NAYAK A, Depasquale B, Vergara N, Guzzo TA, et al
    Villous Adenoma Arising in the Native Bladder Mucosa and the Upper Urinary Tract With Coexisting Neuroendocrine Carcinoma Following Augmentation Cystoplasty.
    Int J Surg Pathol. 2019;27:450-456.
    Abstract    

    Abstract available

  81. KIM JE, Martinez D
    Two uncommon cases of parathyroid hormone-related peptide mediated hypercalcemia in bladder carcinoma.
    Endocrinol Diabetes Nutr. 2019;66:69-70.
    Abstract    



  82. FU YR, Luo Y, Xie X, Lu W, et al
    Nanoscale bubble delivered YCD-TK/Cx26 gene therapeutic system suppresses tumor growth by inducing necrosis of tumor tissues in mouse Xenograft bladder cancer models.
    Eur Rev Med Pharmacol Sci. 2019;23:7338-7349.
    Abstract    

    Abstract available

  83. SCHUBERT T, Renninger M, Schmid MA, Hassan FN, et al
    Prognostic impact of tumor-associated immune cell infiltrates at radical cystectomy for bladder cancer.
    Urol Oncol. 2019 Sep 16. pii: S1078-1439(19)30331.
    Abstract    

    Abstract available

  84. MA Y, Feng XF, Yang WX, You CG, et al
    Exploring the Pathological Mechanism of Bladder Cancer Based on Tumor Mutational Burden Analysis.
    Biomed Res Int. 2019;2019:1093815.
    Abstract    

    Abstract available

  85. GAO X, Zheng W, Ye L, Wen X, et al
    Exploration of bladder cancer-associated methylated miRNAs by methylated DNA immunoprecipitation sequencing.
    Onco Targets Ther. 2019;12:6165-6174.
    Abstract    

    Abstract available

  86. ROMPRE-BRODEUR A, Shinde-Jadhav S, Ayoub M, Piccirillo CA, et al
    PD-1/PD-L1 Immune-Checkpoint Inhibition with Radiation in Bladder Cancer: In Situ and Abscopal Effects.
    Mol Cancer Ther. 2019 Sep 18. pii: 1535-7163.MCT-18-0986.
    Abstract    

    Abstract available

  87. XU X
    Processed meat intake and bladder cancer risk in the prostate, lung, colorectal and ovarian (PLCO) cohort.
    Cancer Epidemiol Biomarkers Prev. 2019 Sep 18. pii: 1055-9965.EPI-19-0604.
    Abstract    

    Abstract available

  88. BOLENZ C, Rother J, Meessen S, Grychtol B, et al
    [The development of real-time multispectral imaging for the diagnostics of bladder cancer].
    Urologe A. 2019 Sep 17. pii: 10.1007/s00120-019-01037.
    Abstract    

    Abstract available

  89. DAI ZW, Cai KD, Li FR, Wu XB, et al
    Association between coffee consumption and risk of bladder cancer in a meta-analysis of 16 prospective studies.
    Nutr Metab (Lond). 2019;16:66.
    Abstract    

    Abstract available

  90. KIM SO, Cha HJ, Park C, Lee H, et al
    Cordycepin induces apoptosis in human bladder cancer T24 cells through ROS-dependent inhibition of the PI3K/Akt signaling pathway.
    Biosci Trends. 2019;13:324-333.
    Abstract    

    Abstract available

  91. KULANDER O, Johansson J, Brudin L
    [Low frequency of cancer in the urinary organs when macroscopic hematuria is associated with bacteriuria].
    Lakartidningen. 2019;116.
    Abstract    

    Abstract available

  92. NORDIN G, Eriksson Boija E
    [Achieving laboratory results you can rely on].
    Lakartidningen. 2019;116.
    Abstract    

    Abstract available

  93. HAN S, Dong K, Shen M, Wang X, et al
    Observation and mechanism study of bladder wound healing after transurethral holmium laser resection of bladder tumor.
    Lasers Med Sci. 2019;34:1217-1227.
    Abstract    

    Abstract available

  94. DARR C, Hadaschik BA, Tschirdewahn S
    [Systemic treatment of metastatic tumors of the upper urinary tract].
    Urologe A. 2019;58:30-33.
    Abstract    

    Abstract available

  95. KNOLL T, Bach T
    [Enhanced endoscopic imaging for urothelial cancer].
    Aktuelle Urol. 2019;50:76-83.
    Abstract    

    Abstract available

  96. GAKIS G, Volkmer B, Qvick B, Marteau F, et al
    [Cost-effectiveness analysis of blue light cystoscopy with hexylaminolevulinate in transurethral resection of the bladder].
    Urologe A. 2019;58:34-40.
    Abstract    

    Abstract available

  97. NESI G, Galli IC, Amorosi A, Santi R, et al
    Environment and urinary bladder cancer. A historical perspective.
    Pol J Pathol. 2019;70:21-25.
    Abstract    

    Abstract available

  98. ZHANG Z, Xu H, Ji J, Shi X, et al
    Heterogeneity of PTEN and PPAR-gamma in cancer and their prognostic application to bladder cancer.
    Exp Ther Med. 2019;18:3177-3183.
    Abstract    

    Abstract available

  99. SIM WJ, Iyengar PV, Lama D, Lui SKL, et al
    c-Met activation leads to the establishment of a TGFbeta-receptor regulatory network in bladder cancer progression.
    Nat Commun. 2019;10:4349.
    Abstract    

    Abstract available

  100. KLEN R, Salminen AP, Mahmoudian M, Syvanen KT, et al
    Prediction of complication related death after radical cystectomy for bladder cancer with machine learning methodology.
    Scand J Urol. 2019 Sep 25:1-7. doi: 10.1080/21681805.2019.1665579.
    Abstract    

    Abstract available

  101. BAUMGART S, Meschkat P, Edelmann P, Heinzelmann J, et al
    MicroRNAs in tumor samples and urinary extracellular vesicles as a putative diagnostic tool for muscle-invasive bladder cancer.
    J Cancer Res Clin Oncol. 2019 Sep 24. pii: 10.1007/s00432-019-03035.
    Abstract    

    Abstract available

  102. DATTA NR, Stutz E, Puric E, Eberle B, et al
    A Pilot Study of Radiotherapy and Local Hyperthermia in Elderly Patients With Muscle-Invasive Bladder Cancers Unfit for Definitive Surgery or Chemoradiotherapy.
    Front Oncol. 2019;9:889.
    Abstract    

    Abstract available

  103. ABUDUREXITI M, Xie H, Jia Z, Zhu Y, et al
    Development and External Validation of a Novel 12-Gene Signature for Prediction of Overall Survival in Muscle-Invasive Bladder Cancer.
    Front Oncol. 2019;9:856.
    Abstract    

    Abstract available

  104. DAZA-CAJIGAL V, Albuquerque AS, Pearson J, Hinley J, et al
    Loss of Janus Associated Kinase 1 Alters Urothelial Cell Function and Facilitates the Development of Bladder Cancer.
    Front Immunol. 2019;10:2065.
    Abstract    

    Abstract available

  105. BOCHNER BH
    Lymph Node Dissection for Advanced Bladder Cancer: Is There a Role?
    Eur Urol Focus. 2019 Sep 21. pii: S2405-4569(19)30284.
    Abstract    

    Abstract available

  106. PARIKH RB, Adamson BJS, Khozin S, Galsky MD, et al
    Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer.
    JAMA. 2019;322:1209-1211.
    Abstract    



  107. HOU G, Xu W, Jin Y, Wu J, et al
    MiRNA-217 accelerates the proliferation and migration of bladder cancer via inhibiting KMT2D.
    Biochem Biophys Res Commun. 2019 Sep 20. pii: S0006-291X(19)31750.
    Abstract    

    Abstract available

  108. LUO Y, Dong Y, Liang S, Yuan L, et al
    CpG Oligodeoxynucleotide Promotes Apoptosis of Human Bladder Cancer T24 Cells Via Inhibition of the Antiapoptotic Factors.
    Technol Cancer Res Treat. 2019;18:1533033819873636.
    Abstract    

    Abstract available

  109. LI W, Li Y, Sun Z, Zhou J, et al
    Comprehensive circular RNA profiling reveals the regulatory role of the hsa_circ_0137606/miR1231 pathway in bladder cancer progression.
    Int J Mol Med. 2019 Sep 17. doi: 10.3892/ijmm.2019.4340.
    Abstract    

    Abstract available

  110. YANG C, Sun X, Wang H, Lu T, et al
    Metabolomic profiling identifies novel biomarkers and mechanisms in human bladder cancer treated with submucosal injection of gemcitabine.
    Int J Mol Med. 2019 Sep 23. doi: 10.3892/ijmm.2019.4347.
    Abstract    

    Abstract available

  111. SHAN L, Liu W, Zhan Y
    Sulfated polysaccharide of Sepiella maindroni ink targets Akt and overcomes resistance to the FGFR inhibitor AZD4547 in bladder cancer.
    Aging (Albany NY). 2019;11.
    Abstract    

    Abstract available

  112. LIU Y, Xiong S, Liu S, Chen J, et al
    Analysis of Gene Expression in Bladder Cancer: Possible Involvement of Mitosis and Complement and Coagulation Cascades Signaling Pathway.
    J Comput Biol. 2019 Sep 23. doi: 10.1089/cmb.2019.0237.
    Abstract    

    Abstract available

  113. MORINAGA R, Kawahara T, Kuroda S, Inayama Y, et al
    Granulocyte Colony-Stimulating Factor-Producing Bladder Cancer.
    Case Rep Oncol. 2019;12:603-607.
    Abstract    

    Abstract available

  114. BHUSHAN S, Ray RS, Prakash J, Singh GN, et al
    Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis.
    Clin Ther. 2019 Sep 19. pii: S0149-2918(19)30422.
    Abstract    

    Abstract available

  115. ORTIZ-BRUCHLE N, Muders M, Toma M, Esposito I, et al
    [Status of the availability and use of next generation sequencing (NGS) in bladder cancer-a questionnaire within the uropathology working group].
    Urologe A. 2019 Sep 20. pii: 10.1007/s00120-019-01046.
    Abstract    

    Abstract available

  116. HU X, Xiong SC, Dou WC, Shao YX, et al
    Minimally invasive vs open radical cystectomy in patients with bladder cancer: A systematic review and meta-analysis of randomized controlled trials.
    Eur J Surg Oncol. 2019 Sep 13. pii: S0748-7983(19)30808.
    Abstract    

    Abstract available

  117. JANISCH F, Yu H, Vetterlein MW, Dahlem R, et al
    Do Younger Patients with Muscle-Invasive Bladder Cancer have Better Outcomes?
    J Clin Med. 2019;8.
    Abstract    

    Abstract available

  118. MOSCHINI M, Stabile A, Mattei A, Montorsi F, et al
    Enhanced recovery after surgery (ERAS) in radical cystectomy patients: from consensus to evidences.
    Int Braz J Urol. 2019;45:655-657.
    Abstract    



  119. BASATAC C, Aktepe F, Saglam S, Akpinar H, et al
    Synchronous presentation of muscle-invasive urothelial carcinoma of bladder and peritoneal malign mesothelioma.
    Int Braz J Urol. 2019;45:843-846.
    Abstract    

    Abstract available

  120. CASTELLANI D, Gasparri L, Claudini R, Pavia MP, et al
    Iatrogenic foreign body in urinary bladder: Holmium laser vs. Ceramic, and the winner is....
    Int Braz J Urol. 2019;45:853.
    Abstract    

    Abstract available

  121. CHEN M, Tsai YT, Chang WS, Shih LC, et al
    Association of Caspase-8 Genotypes With Bladder Cancer Risk.
    Anticancer Res. 2019;39:4767-4773.
    Abstract    

    Abstract available

  122. ZHENG J, Kong J, Wu S, Li Y, et al
    Development of a noninvasive tool to preoperatively evaluate the muscular invasiveness of bladder cancer using a radiomics approach.
    Cancer. 2019 Aug 30. doi: 10.1002/cncr.32490.
    Abstract    

    Abstract available

  123. BABJUK M, Burger M, Comperat EM, Gontero P, et al
    European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
    Eur Urol. 2019 Aug 20. pii: S0302-2838(19)30660.
    Abstract    

    Abstract available

  124. VARMA M, Delahunt B, Kwast TV
    Reply to Eva Comperat, Mahul Amin, Victor Reuter's Editorial Reply re: Murali Varma, Brett Delahunt, Theodorus van der Kwast. Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. Eur Urol. In press. htt
    Eur Urol. 2019 Aug 29. pii: S0302-2838(19)30676.
    Abstract    



  125. YANG A, Cannataro VL, Townsend JP
    Re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019;76:9-13.
    Eur Urol. 2019 Aug 29. pii: S0302-2838(19)30662.
    Abstract    



  126. SHI MJ, Meng XY, Chen CL, Dyrskjot L, et al
    Reply to Alexander Yang, Vincent L. Cannataro, Jeffrey P. Townsend's Letter to the Editor, re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as, a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Can
    Eur Urol. 2019 Sep 4. pii: S0302-2838(19)30656.
    Abstract    



  127. NOHARA T, Kato Y, Nakano T, Nakagawa T, et al
    Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2019 Sep 11. doi: 10.1111/iju.14099.
    Abstract    

    Abstract available

  128. CHOO SH, Nishiyama H, Kitamura H, Chen CH, et al
    Practice pattern of non-muscle invasive bladder cancer in Japan, Korea and Taiwan: A Web-based survey.
    Int J Urol. 2019 Sep 11. doi: 10.1111/iju.14105.
    Abstract    

    Abstract available

  129. KHANNA A, Saarela O, Lawson K, Finelli A, et al
    Hospital Quality Metrics for Radical Cystectomy: Disease Specific and Correlated to Mortality Outcomes.
    J Urol. 2019;202:490-497.
    Abstract    

    Abstract available

  130. MOREY AF
    Re: Dual Prosthetic Implantation after Radical Cystoprostatectomy and Neobladder: Outcomes of the Inflatable Penile Prosthesis and Artificial Urinary Sphincter in Bladder Cancer Survivors.
    J Urol. 2019 Sep 13:101097JU0000000000000549. doi: 10.1097/JU.0000000000000549.
    Abstract    



  131. ATALA A
    Re: Bladder Cancer Extracellular Vesicles Drive Tumorigenesis by Inducing the Unfolded Protein Response in Endoplasmic Reticulum of Nonmalignant Cells.
    J Urol. 2019 Sep 12:10109701JU00005851520364998.
    Abstract    



  132. GRIEBLING TL
    Re: The Feasibility and Safety of Reproductive Organ Preserving Radical Cystectomy for Elderly Female Patients with Muscle-Invasive Bladder Cancer: A Retrospective Propensity Score-Matched Study.
    J Urol. 2019 Sep 18:101097JU0000000000000559. doi: 10.1097/JU.0000000000000559.
    Abstract    



  133. GRIEBLING TL
    Re: Disparities in Bladder Cancer Treatment and Survival amongst Elderly Patients with a Pre-Existing Mental Illness.
    J Urol. 2019 Sep 18:10109701JU00005857524193298.
    Abstract    



  134. CHANG SS
    Re: Prognostic Significance of Lymphatic, Vascular and Perineural Invasion for Bladder Cancer Patients Treated by Radical Cystectomy.
    J Urol. 2019 Sep 18:10109701JU0000585772800505.
    Abstract    



  135. GRIEBLING TL
    Re: High-Precision Bladder Cancer Irradiation in the Elderly: Clinical Results for a Plan-of-the-Day Integrated Boost Technique with Image Guidance Using Lipiodol Markers.
    J Urol. 2019 Sep 18:10109701JU00005857643430962.
    Abstract    



  136. GRIEBLING TL
    Re: Cost-Effectiveness of Surveillance Schedules in Older Adults with Non-Muscle-Invasive Bladder Cancer.
    J Urol. 2019 Sep 18:10109701JU00005857564955687.
    Abstract    



  137. GRIEBLING TL
    Re: Evaluation of Cause of Death after Radical Cystectomy for Patients with Bladder Cancer: The Impact of Age at the Time of Surgery.
    J Urol. 2019 Sep 18:10109701JU000058576026685.
    Abstract    



  138. CHANG SS
    Re: Cost-Effectiveness of Pembrolizumab in Second-Line Advanced Bladder Cancer.
    J Urol. 2019 Sep 18:10109701JU000058576872427.
    Abstract    



  139. LIEM EI, Oddens JR, Vernooij R, Li R, et al
    The Role of Fluorescence in Situ Hybridization for Predicting Recurrence after Adjuvant Bacillus Calmette-Guerin in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer Patients: A Systematic Review and Meta-Analysis of Individual Patient Da
    J Urol. 2019 Sep 24:101097JU0000000000000566. doi: 10.1097/JU.0000000000000566.
    Abstract    

    Abstract available

  140. CHEN J, Chou F, Yeh S, Ou Z, et al
    Androgen dihydrotestosterone (DHT) promotes the bladder cancer nuclear AR-negative cell invasion via a newly identified membrane androgen receptor (mAR-SLC39A9)-mediated Galphai protein/MAPK/MMP9 intracellular signaling.
    Oncogene. 2019 Sep 10. pii: 10.1038/s41388-019-0964.
    Abstract    

    Abstract available

  141. NEUZILLET Y, Geiss R, Caillet P, Paillaud E, et al
    [Epidemiological, pathological and prognostic characteristics of bladder cancer in elderly patients].
    Prog Urol. 2019 Aug 27. pii: S1166-7087(19)30456.
    Abstract    

    Abstract available

  142. YOO SH, Kim H, Kwak C, Kim HH, et al
    Late Recurrence of Bladder Cancer following Radical Cystectomy: Characteristics and Outcomes.
    Urol Int. 2019 Aug 28:1-6. doi: 10.1159/000502656.
    Abstract    

    Abstract available

  143. CARANDO R, Zazzara M, Cotrufo S, Ludovico GM, et al
    Intravesical Treatment with Electro-Mediated Administration of Mytomicin C as Prophylaxis for Intermediate and High-Risk Nonmuscle-Invasive Bladder Cancer: A Retrospective Multicenter Study.
    Urol Int. 2019 Aug 28:1-6. doi: 10.1159/000502663.
    Abstract    

    Abstract available

  144. AJAJ R, Berlin A, Klaassen Z, Chandrasekar T, et al
    Age differences in patient-reported psychological and physical distress symptoms in bladder cancer patients - A Cross Sectional Study.
    Urology. 2019 Sep 2. pii: S0090-4295(19)30786.
    Abstract    

    Abstract available

  145. YUK HD, Jeong CW, Kwak C, Kim HH, et al
    Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification.
    BMC Cancer. 2019;19:897.
    Abstract    

    Abstract available

  146. WANG CC, Tsai YC, Jeng YM
    Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancer.
    PLoS One. 2019;14:e0221785.
    Abstract    

    Abstract available

  147. ZHU Z, Zhao J, Li Y, Pang C, et al
    Prognostic value of preoperative hydronephrosis in patients with bladder cancer undergoing radical cystectomy: A meta-analysis.
    PLoS One. 2019;14:e0222223.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;